Company: GRCE
Filing Date: 2025-03-10
Form Type: S-3
Source: 0001140361-25-007769
Chunk: 11

Company: Grace Therapeutics, Inc.
Filing Date: 2025-03-10
Form: S-3
Chunk 11
---
 unit eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. IV delivery of GTx-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTx-104 has the potential to better manage hypotension in aSAH patients.

| • | GTx-102 is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia, a complex orphan pediatric genetic 
 neurodegenerative disorder usually diagnosed in young children, for which no FDA approved treatment currently exists.         |

| • | GTx-101 is a topical bio adhesive film-forming bupivacaine spray for PHN, which can be persistent and often causes                                                         
 debilitating pain following infection by the shingles virus. We believe that GTx-101 could be administered to patients with PHN to treat pain associated with the disease. |

In May 2023, we announced the strategic decision to prioritize development of GTx-104 with a goal to GTx-104 to commercialization, while conserving resources as much as possible to complete development efficiently. We estimate that the deferral of GTx-102 and GTx-101 clinical development could be at least three years given the timeline to complete the development and potential commercial launch of GTx-104. Further development of GTx-102 and GTx-101 will occur at such time as we obtain additional funding or enter into strategic partnerships for license or sale with third parties. Description of the Transaction 2025 Private Placement On February 10, 2025, we sold in the Private Placement Offering an aggregate of 3,252,132 shares of Common Stock, at a purchase price of $3.395 per Share, and Pre-Funded Warrants to purchase up to 1,166,160 shares of Common Stock, at a purchase price equal to the purchase price per Share less $0.0001. Each Pre-Funded Warrant is exercisable for one share of Common Stock at an exercise price of $0.0001 per share, is exercisable immediately and will expire once exercised in full. For each Share and Pre-Funded Warrant issued, we issued to each purchaser an accompanying Common Warrant to purchase shares of Common Stock (or Pre-Funded Warrants in lieu thereof), exercisable for an aggregate of 4,418,292 shares of Common Stock (or Pre-Funded Warrants in lieu thereof). Each